Physician profile
David D Gilbert
NPI 1033297536
$2,559.05
in general payments reported to CMS, 2019-2025
15 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $126 · 2021: $214 · 2022: $124 · 2023: $427 · 2024: $270 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $802.21 | 2019-2021 | |
| Alcon Vision LLC | $739.66 | 2019-2025 | Rocklatan, Rhopressa, Clareon |
| Abbvie INC. | $431.89 | 2023-2025 | |
| Oyster Point Pharma, INC. | $233.92 | 2022-2024 | Tyrvaya |
| Nevro Corp. | $80.86 | 2019 | |
| Thea Pharma INC. | $58.97 | 2023-2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $50.55 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $41.27 | 2023-2024 | Miebo, Prolensa, Alrex |
| Beaver-Visitec International, INC. | $19.69 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $18.61 | 2024 | Xdemvy |
| Sight Sciences, INC. | $17.58 | 2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $15.54 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.31 | 2019 | |
| Nobel Biocare USA | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.